NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Inno Peptides

Published 12 Nov 2026. 36-page investigative report on who is behind Inno Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 78 Finnrick lab tests, Inno Peptides posts a 73% overall pass rate (57 pass / 20 fail). The record is uneven rather than uniformly bad: GHK-Cu is the strongest relative row, Retatrutide has a majority-pass record but the largest absolute failure count, and MOTS-c plus Tesamorelin are avoid-at-current-evidence products. Ratings also compress under stricter purity/fill assumptions, so lot verification matters.

The bigger public-channel problem is domain control. RDAP/WHOIS show the historical innopeptides.com registration was replaced by a privacy-protected record using parking nameservers, while innopeptides.com and es.innopeptides.com now route to advertising/parking infrastructure. LinkedIn still points buyers to the dead domain, and no vendor-operated replacement storefront was found.

Operating attribution is stronger than ownership attribution: records converge on Wuhan Yingnuo Technology / Wuhan INNO at the World Trade Building 2105/2105C office in Wuhan, but no shareholder, legal-representative or natural-person controller record was obtained. The full report also separates this vendor from the similarly named InnoPeptide and examines an inno-peptides.com WooCommerce lookalike using InnoPeptide assets with no reliable contact details. Parasite-SEO pages redirect Inno searches toward WhatsApp funnels.

The reputation file is mixed. Some community reports show orders still arriving through private channels during the outage, but the same public record includes a branded-Jintropin HGH authenticity dispute described as high copy, reship-fee and blocking allegations, and crypto/wire-style payment exposure. Those findings do not prove the tested peptides failed; they affect authenticity checks and buyer recourse.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for all 7 tested peptides
  • RDAP/WHOIS exhibits and redirect-flow analysis for the parked historical domain
  • Corporate-attribution files for Wuhan INNO, 武汉映诺科技有限公司 and the Room 2105 office
  • Brand-disambiguation analysis of Inno Peptides, InnoPeptide and the inno-peptides.com lookalike
  • Reputation exhibits covering Jintropin, direct-message sales, payment recourse and Trustpilot removal

Risk assessment

  • Official-channel integrity risk — high: The historical innopeptides.com domain and es.innopeptides.com are parked/ad redirects after the 2026-09-11 re-registration; no vendor-operated replacement storefront was found.
  • Brand-confusion and copycat risk — high: inno-peptides.com uses InnoPeptide assets and no contact details; parasite-SEO/WhatsApp funnels intercept searches; the subject publishes no current official-channel or anti-counterfeit list.
  • Ownership and control opacity risk — high: Operating records point to Wuhan Yingnuo / Wuhan INNO at Room 2105, but no natural-person UBO, shareholder or legal-representative record was obtained; multiple trading names remain in use.
  • Product quality risk — Retatrutide — high: Retatrutide has 32 tests, 26 pass / 6 fail, 79.83%; it carries the largest absolute failure count in the current Finnrick record.
  • Product quality risk — Tirzepatide and Cagrilintide — medium: Tirzepatide has 15 tests, 11 pass / 4 fail, 74.06%; Cagrilintide has 3 tests, 2 pass / 1 fail, 56.48%; both require lot-specific verification.
  • Product quality risk — MOTS-c and Tesamorelin — high: MOTS-c has 6 tests, 2 pass / 4 fail, 33.18%; Tesamorelin has 5 tests, 1 pass / 4 fail, 41.51%; these are avoid-at-current-evidence products.
  • Branded-HGH authenticity risk — high: The 2024 Jintropin dispute records failed Gen-Sci verification and vendor-side language describing the product as high copy; this is product-specific to branded HGH.
  • Buyer recourse and payment risk — high: Direct-message sales, crypto/wire-style payments, reship-fee allegations and blocking complaints leave buyers with weak practical remedies if a package, payment or lot goes wrong.